Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysisResearch in context
Background: Understanding the impact of CYP2D6 metabolism on paroxetine, a widely used antidepressant, is essential for precision dosing. Methods: We conducted an 8-week, multi-center, single-drug, 2-week wash period prospective cohort study in 921 Chinese Han patients with depressive or anxiety dis...
Saved in:
Published in | EBioMedicine Vol. 104; p. 105165 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier
01.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Understanding the impact of CYP2D6 metabolism on paroxetine, a widely used antidepressant, is essential for precision dosing. Methods: We conducted an 8-week, multi-center, single-drug, 2-week wash period prospective cohort study in 921 Chinese Han patients with depressive or anxiety disorders (ChiCTR2000038462). We performed CYP2D6 genotyping (single nucleotide variant and copy number variant) to derive the CYP2D6 activity score and evaluated paroxetine treatment outcomes including steady-state concentration, treatment efficacy, and adverse reaction. CYP2D6 metabolizer status was categorized into poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), and ultrarapid metabolizers (UMs). The influence of CYP2D6 metabolic phenotype on paroxetine treatment outcomes was examined using multiple regression analysis and cross-ethnic meta-analysis. The therapeutic reference range of paroxetine was estimated by receiver operating characteristic (ROC) analyses. Findings: After adjusting for demographic factors, the steady-state concentrations of paroxetine in PMs, IMs, and UMs were 2.50, 1.12, and 0.39 times that of EMs, with PM and UM effects being statistically significant (multiple linear regression, P = 0.03 and P = 0.04). Sex and ethnicity influenced the comparison between IMs and EMs. Moreover, poor efficacy of paroxetine was associated with UM, and a higher risk of developing adverse reactions was associated with lower CYP2D6 activity score. Lastly, cross-ethnic meta-analysis suggested dose adjustments for PMs, IMs, EMs, and UMs in the East Asian population to be 35%, 40%, 143%, and 241% of the manufacturer's recommended dose, and 62%, 68%, 131%, and 159% in the non-East Asian population. Interpretation: Our findings advocate for precision dosing based on the CYP2D6 metabolic phenotype, with sex and ethnicity being crucial considerations in this approach. Funding: National Natural Science Foundation of China; Academy of Medical Sciences Research Unit. |
---|---|
AbstractList | Background: Understanding the impact of CYP2D6 metabolism on paroxetine, a widely used antidepressant, is essential for precision dosing. Methods: We conducted an 8-week, multi-center, single-drug, 2-week wash period prospective cohort study in 921 Chinese Han patients with depressive or anxiety disorders (ChiCTR2000038462). We performed CYP2D6 genotyping (single nucleotide variant and copy number variant) to derive the CYP2D6 activity score and evaluated paroxetine treatment outcomes including steady-state concentration, treatment efficacy, and adverse reaction. CYP2D6 metabolizer status was categorized into poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), and ultrarapid metabolizers (UMs). The influence of CYP2D6 metabolic phenotype on paroxetine treatment outcomes was examined using multiple regression analysis and cross-ethnic meta-analysis. The therapeutic reference range of paroxetine was estimated by receiver operating characteristic (ROC) analyses. Findings: After adjusting for demographic factors, the steady-state concentrations of paroxetine in PMs, IMs, and UMs were 2.50, 1.12, and 0.39 times that of EMs, with PM and UM effects being statistically significant (multiple linear regression, P = 0.03 and P = 0.04). Sex and ethnicity influenced the comparison between IMs and EMs. Moreover, poor efficacy of paroxetine was associated with UM, and a higher risk of developing adverse reactions was associated with lower CYP2D6 activity score. Lastly, cross-ethnic meta-analysis suggested dose adjustments for PMs, IMs, EMs, and UMs in the East Asian population to be 35%, 40%, 143%, and 241% of the manufacturer's recommended dose, and 62%, 68%, 131%, and 159% in the non-East Asian population. Interpretation: Our findings advocate for precision dosing based on the CYP2D6 metabolic phenotype, with sex and ethnicity being crucial considerations in this approach. Funding: National Natural Science Foundation of China; Academy of Medical Sciences Research Unit. |
Author | Weihua Yue Saizheng Weng Yong Zhang Xialong Cheng Jiaojiao Xiang Maolin Hu Bing Li Jiyang Pan Yuxiang He Chunyan Zhu Yundan Liao Ruiqian Lin Rongyan Zheng Jing Guo Hua-ning Wang Zhongchun Liu Ruhong Jiang Jun Wang Anzhen Wang Jian Zhang Lidong Sun Di Wu Ji-ting Geng Kai Wang Jian-min Zhang Zhi-yu Chen Yong-can Zhou Xiao-yan Zhai Wei-xin Wang Yutao Sun Yaoyao Sun Yuyanan Zhang Guifang Liu Jiong He Yan Yang Hanping Bai Wenmei Fang Chengchen Huang Ai-hua Ni Huailiang Yang Xin Sun Fangyi Deng Yifan Sun Changbin Cao Rui Tang Yunshu Zhang Yi-huan Chen Li Kuang Lili Peng Ting Zhang Zhewei Kang Hui Yu Jingshan Han |
Author_xml | – sequence: 1 fullname: Yundan Liao organization: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China – sequence: 2 fullname: Yutao Sun organization: Department of Psychiatry, The Fifth Hospital of Tangshan, Tangshan, Hebei, China – sequence: 3 fullname: Jing Guo organization: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China – sequence: 4 fullname: Zhewei Kang organization: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China – sequence: 5 fullname: Yaoyao Sun organization: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China – sequence: 6 fullname: Yuyanan Zhang organization: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China – sequence: 7 fullname: Jiong He organization: Shanghai Conlight Medical Laboratory Co., Ltd, Shanghai, China – sequence: 8 fullname: Chengchen Huang organization: Shanghai Conlight Medical Laboratory Co., Ltd, Shanghai, China – sequence: 9 fullname: Xin Sun organization: Shanghai Conlight Medical Laboratory Co., Ltd, Shanghai, China – sequence: 10 fullname: Jian-min Zhang organization: Tongde Hospital of Zhejiang Province (Zhejiang Mental Health Center), Hangzhou, Zhejiang, China – sequence: 11 fullname: Jun Wang organization: The Affiliated Mental Health Center of Jiangnan University, Wuxi, Jiangsu, China – sequence: 12 fullname: Hua-ning Wang organization: The First Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, China – sequence: 13 fullname: Zhi-yu Chen organization: Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University, Hangzhou, Zhejiang, China – sequence: 14 fullname: Kai Wang organization: Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, Anhui, China – sequence: 15 fullname: Jiyang Pan organization: Department of Psychiatry, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China – sequence: 16 fullname: Ai-hua Ni organization: Department of Clinical Psychology, Hebei General Hospital, Shijiazhuang, Hebei, China – sequence: 17 fullname: Saizheng Weng organization: Fuzhou Neuropsychiatric Hospital, Fuzhou, Fujian, China – sequence: 18 fullname: Anzhen Wang organization: Hefei Fourth People's Hospital, Hefei, Anhui, China – sequence: 19 fullname: Changbin Cao organization: Weihai Mental Health Center, Weihai, Shandong, China – sequence: 20 fullname: Lidong Sun organization: The Fourth People's Hospital of Ordos, Ordos, Inner Mongolia, China – sequence: 21 fullname: Yong Zhang organization: Tianjin Anding Hospital, Tianjin, China – sequence: 22 fullname: Li Kuang organization: Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Corresponding author – sequence: 23 fullname: Yunshu Zhang organization: Hebei Provincial Mental Health Center, Hebei Key Laboratory of Major Mental and Behavioral Disorders, The Sixth Clinical Medical College of Hebei University, Baoding, Hebei, China; Corresponding author – sequence: 24 fullname: Zhongchun Liu organization: Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, China; Corresponding author – sequence: 25 fullname: Weihua Yue organization: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China; Chinese Institute for Brain Research, Beijing, China; PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, China; Corresponding author. Institute of Mental Health, Peking University Sixth Hospital, No. 51 Hua Yuan Bei Road, Beijing, 100191, PR China – sequence: 26 fullname: Yundan Liao – sequence: 27 fullname: Yutao Sun – sequence: 28 fullname: Jing Guo – sequence: 29 fullname: Zhewei Kang – sequence: 30 fullname: Yaoyao Sun – sequence: 31 fullname: Yuyanan Zhang – sequence: 32 fullname: Hanping Bai – sequence: 33 fullname: Maolin Hu – sequence: 34 fullname: Bing Li – sequence: 35 fullname: Jingshan Han – sequence: 36 fullname: Jiaojiao Xiang – sequence: 37 fullname: Ruhong Jiang – sequence: 38 fullname: Jian Zhang – sequence: 39 fullname: Yuxiang He – sequence: 40 fullname: Huailiang Yang – sequence: 41 fullname: Guifang Liu – sequence: 42 fullname: Lili Peng – sequence: 43 fullname: Hui Yu – sequence: 44 fullname: Xialong Cheng – sequence: 45 fullname: Wenmei Fang – sequence: 46 fullname: Rongyan Zheng – sequence: 47 fullname: Ruiqian Lin – sequence: 48 fullname: Xiao-yan Zhai – sequence: 49 fullname: Rui Tang – sequence: 50 fullname: Fangyi Deng – sequence: 51 fullname: Chunyan Zhu – sequence: 52 fullname: Ting Zhang – sequence: 53 fullname: Yan Yang – sequence: 54 fullname: Ji-ting Geng – sequence: 55 fullname: Di Wu – sequence: 56 fullname: Yi-huan Chen – sequence: 57 fullname: Yifan Sun – sequence: 58 fullname: Yong-can Zhou – sequence: 59 fullname: Wei-xin Wang – sequence: 60 fullname: Jian-min Zhang – sequence: 61 fullname: Jun Wang – sequence: 62 fullname: Hua-ning Wang – sequence: 63 fullname: Zhi-yu Chen – sequence: 64 fullname: Kai Wang – sequence: 65 fullname: Jiyang Pan – sequence: 66 fullname: Ai-hua Ni – sequence: 67 fullname: Saizheng Weng – sequence: 68 fullname: Anzhen Wang – sequence: 69 fullname: Changbin Cao – sequence: 70 fullname: Lidong Sun – sequence: 71 fullname: Yong Zhang – sequence: 72 fullname: Li Kuang – sequence: 73 fullname: Yunshu Zhang – sequence: 74 fullname: Zhongchun Liu – sequence: 75 fullname: Weihua Yue |
BookMark | eNqtjUFOw0AMRSMEEgV6B18gUppMS2HbgsoOITasInfGIa7SmcieloSzchimFUdgZen5672b7NIHTxfZpKzmZV49LMx1NlXdFUUxm5sEl5PsZx2UAN3uoHFPPkJooEcJA0X2BFtUchA8rD5ey_UC0EY-chxBbRAC9g2JpMWeIm5Dx98koBHjQdMPVm1yJP0GfZJGTn6FL44tOOqFVPlIEATQD0xJ6liDOBJ9BIRegvZ06lFSHtyYZg5soppTbD3bczVHj92orG-phGLbU9gGH2mId9lVg53S9O_eZi_PT--rTe4C7upeeI8y1gG5PoMgnzVKZNtRbRZ2TiVVtikKY2YVFmQJnSltaZb3VVP9p-sXoXKQSQ |
ContentType | Journal Article |
DBID | DOA |
DatabaseName | DOAJ Directory of Open Access Journals |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2352-3964 |
ExternalDocumentID | oai_doaj_org_article_46c5e2e3cf004413a0ecead42c24873f |
GroupedDBID | .1- .FO 0R~ 0SF 457 53G 5VS 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAMRU AAXUO ABMAC ACGFS ADBBV ADEZE ADVLN AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BCNDV EBS FDB GROUPED_DOAJ HZ~ KQ8 M41 M48 NCXOZ OK1 ROL RPM SSZ Z5R |
ID | FETCH-doaj_primary_oai_doaj_org_article_46c5e2e3cf004413a0ecead42c24873f3 |
IEDL.DBID | DOA |
IngestDate | Fri Oct 04 13:08:27 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-doaj_primary_oai_doaj_org_article_46c5e2e3cf004413a0ecead42c24873f3 |
OpenAccessLink | https://doaj.org/article/46c5e2e3cf004413a0ecead42c24873f |
ParticipantIDs | doaj_primary_oai_doaj_org_article_46c5e2e3cf004413a0ecead42c24873f |
PublicationCentury | 2000 |
PublicationDate | 2024-06-01 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | EBioMedicine |
PublicationYear | 2024 |
Publisher | Elsevier |
Publisher_xml | – name: Elsevier |
SSID | ssj0001542358 |
Score | 4.6237254 |
Snippet | Background: Understanding the impact of CYP2D6 metabolism on paroxetine, a widely used antidepressant, is essential for precision dosing. Methods: We conducted... |
SourceID | doaj |
SourceType | Open Website |
StartPage | 105165 |
SubjectTerms | Copy number variant CYP2D6 Dose adjustment Metabolizer status Paroxetine Precision medicine |
Title | Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysisResearch in context |
URI | https://doaj.org/article/46c5e2e3cf004413a0ecead42c24873f |
Volume | 104 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS8NAEF2kIHgRP1GrMgevwWY3SVNv2lqqB_GgUE9hu5nFiiYlSaX6W_0xzmxSqCcPek2GHTIbZmaT994IcRZ2LepenHp0eEAvsMr3YjL1ECPlpzY20ji1z7to9BjcjsPxyqgvxoTV8sB14M6DyIQoURnL_x59pTto6OkDaST12sq67OuHK4epmh8cMAf0hxC_qxjDLbHZtHpwWbvYFmuY7Yj1evjjx674GuQlgk5f5qVDekNuYaaLfMEkZAQuLynkGfSf7uUgAiYg8JwHKFl4EhhEVRRk8YYV7ePr9BMLYHbQvKR7wGOxkZYf6Qwa6dQS-JsrLKGv7wh5ATpbMGgT0kaEs7wADZRUlwRMcPKzZJaCq6ceVs_Z1Divnm4ETZboPXbM0HfK93viZnj90B95HJhkVktaJCwy7S5Q6JMm9MlvoVf7opXlGR4I4AkeUvUiayJqAU13YuJeJ7BaBRMZWUwPxdXf_R39xyJtsSGpL6nRXseiVRVzPKG-opqculfoGyig2_k |
link.rule.ids | 315,786,790,2115 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dose+adjustment+of+paroxetine+based+on+CYP2D6+activity+score+inferred+metabolizer+status+in+Chinese+Han+patients+with+depressive+or+anxiety+disorders%3A+a+prospective+study+and+cross-ethnic+meta-analysisResearch+in+context&rft.jtitle=EBioMedicine&rft.au=Yundan+Liao&rft.au=Yutao+Sun&rft.au=Jing+Guo&rft.au=Zhewei+Kang&rft.date=2024-06-01&rft.pub=Elsevier&rft.eissn=2352-3964&rft.volume=104&rft.spage=105165&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_46c5e2e3cf004413a0ecead42c24873f |